GlassScriptPhysician profile
Adam D Perzin
NPI 1104879501
$4,413.58
in general payments reported to CMS, 2019-2025
36 companies · $1,088 in 2025
The $1,088 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $658 · 2020: $1,961 · 2021: $499 · 2022: $156 · 2023: $13.97 · 2024: $37.85 · 2025: $1,088.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $872 · Food and Beverage: $267.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $872.00 |
| Food and Beverage | $267.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dendreon Pharmaceuticals LLC | $1,740.57 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $956.62 | 2019-2025 | |
| Janssen Biotech, INC. | $304.29 | 2019-2025 | Erleada |
| Neotract INC. | $220.61 | 2019-2020 | |
| Procept Biorobotics Corporation | $168.83 | 2025 | |
| Teleflex LLC | $148.68 | 2021-2024 | Solesta |
| Astellas Pharma US INC | $147.30 | 2019-2021 | |
| Ferring Pharmaceuticals INC. | $84.34 | 2019 | |
| Pfizer INC. | $78.91 | 2019-2023 | |
| Medtronic USA, INC. | $73.00 | 2019-2020 | |
| Medtronic, INC. | $72.09 | 2021 | |
| Antares Pharma, INC. | $57.05 | 2019-2021 | |
| Axonics, INC. | $56.80 | 2021 | |
| Olympus America INC. | $29.06 | 2025 | Cysto-Nephro Videoscope |
| Urovant Sciences INC | $28.97 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $28.35 | 2021 | |
| 180 Medical, INC. | $25.16 | 2021 | |
| Palette Life Sciences, INC. | $17.33 | 2022 | |
| Merck Sharp & Dohme LLC | $17.30 | 2024 | Keytruda |
| Verity Pharmaceuticals INC. | $17.20 | 2021 | |
| Tolmar Pharmaceuticals, INC. | $14.89 | 2019 | |
| Allergan, INC. | $14.27 | 2019 | |
| Amgen INC. | $14.26 | 2019 | |
| Genzyme Corporation | $14.06 | 2020 | |
| Shire North American Group INC | $13.93 | 2019 | |
| Myovant Sciences INC. | $13.09 | 2021 | |
| Zyla Life Sciences, INC. | $12.76 | 2019 | |
| Metuchen Pharmaceuticals | $11.78 | 2019 | |
| Endo Pharmaceuticals INC. | $11.59 | 2021 | |
| Photocure INC | $11.43 | 2019 | |
| Clarus Therapeutics INC. | $9.06 | 2021 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Perzin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.